Backgrounds/Aims: We evaluated the clinical usability of immune cell monitoring in adult liver transplantation (LT) recipients. Methods: This study was composed of two parts as using calcineurin phosphatase (CNP) activity assay and ImmuKnow assay independently as in vitro monitoring tools of immune cell function in adult LT recipients. Results: There was a rough correlation between CNP activity and tacrolimus concentration in 33 patients. This association was evident in patients who were only administered tacrolimus, but disappeared after the co-administration of mycophenolate. In 118 healthy individuals, the mean proportion of helper T-cells was 37.4±8.1%. According to ImmuKnow assay, their immune responses were strong in 12 patients (10.2%), moderate in 92 patients (78.0%), and low in 14 patients (11.9%). In 85 patients waiting for LT, there was a rough correlation between the ImmuKnow ATP level and age. Their immune responses were strong in 0 patients (0%), moderate in 8 patients (9.4%), and low in 77 patients (90.6%). There was a difference in the ImmuKnow ATP levels between healthy individuals and patients with liver disease. In 137 LT recipients, there was no correlation between the ImmuKnow ATP levels and tacrolimus concentration. This trend did not change after grouping the patients according to co-administration with mycophenolate. Eight recipients experienced acute rejection, but none showed strong immune response. Conclusions: We think that both CNP activity assay and ImmuKnow assay are too limited to objectively determine the level of immunosuppression. 
INTRODUCTION
Liver transplantation (LT) has been accepted as an established treatment for end-stage liver diseases for the past three decades. Lifelong immunosuppression is essential for every LT recipient, but currently there are few institutional immunosuppression protocols that are applicable to recipients who survive for a long period of time. [1] [2] [3] Thus, there is a real need to establish tailored, long-term, immunosuppressive regimens that are applicable to LT recipients and can be administered for life.
Posttransplant patient survival with good graft function for many years indicates the possibility of some immune tolerance. 4 Withdrawing immunosuppression has been attempted by a small number of clinical trials, but most of these studies report similar conclusions, in that there is a low possibility of induced operational tolerance in current immunosuppressive clinical settings. [5] [6] [7] [8] If there were some reliable methods for assessing immune function, they could be used for immune monitoring of operational tolerance and the tailored adjustment of immunosuppression protocols in LT recipients. Several specified bioassays, such as regulatory T-cell assays, helper T-cell assays, cytokine gene polymorphism assays, donor-specific antigen measurement, microarrays, and others are used for this purpose, 4 but a reliable surrogate biomarker of immune tolerance has not been discovered. Because CNIs target T-cell function, CD4 cells are used for this assay.
In our present study, we assessed the clinical usability of the CNP activity assay and ImmuKnow assay as in vitro monitoring tools of immune cell function in adult LT recipients.
MATERIALS AND METHODS

Study design and patient selection
This prospective study was composed of 2 parts: independently applying the CNP activity assay or ImmuKnow assay to different study patients. All study patients were inpatients in the early posttransplant period, or readmission and outpatients undergoing routine follow-up after LT. The CNP activity assay was performed on 33 patients. These patients were selected according to their posttransplant period as follows: 15 recipients within 1 month after LT; 9 recipients after 1-12 months; 8 patients after 1-10 years; and 1 patient who had complete immunosuppression withdrawal for 10 years. All patients were administered tacrolimus at the time of blood sampling except one patient who had already completed immunosuppression withdrawal.
For the ImmuKnow assay, 118 young healthy individuals undergoing preoperative living-donor work-up were enrolled as a control group. The study group included 137 recipients who were selected according to the posttransplant period as follows: 77 recipients within 1 month after LT; 43 recipients within 1-12 months; and 17 patients within 1-10 years. All patients were administered tacrolimus at the time of blood sampling. Of these patients, 85
patients were also evaluated using the ImmuKnow assay a few days before LT.
For each assay, peripheral blood samples (5 ml) were collected in sodium heparin tubes on the day of blood collection. None of the results from these assays was used for clinical purposes, diagnosis, or treatment. The study protocol was approved by the institutional review board of Asan Medical Center (2014-0875).
Immunosuppression protocols
The peritransplant primary immunosuppression protocol that is administered to adult LT recipients at our institution consists of an interleukin-2 receptor inhibitor (basiliximab) on days 0 and 4; an intraoperative steroid bolus injection thus, for convenience, we express CNP activity using a unit of 1 nmol/10 6 cells.
ImmuKnow assay
ImmuKnow is an immune cell function assay that de- 
Statistical analysis
The continuous variables are presented as the mean±SD or median. The student t-test was used for comparisons.
In this study, p＜0.05 was considered statistically 
RESULTS
CNP activity in LT recipients
The demographic profiles of the 33 patients who were evaluated using the CNP activity assay are summarized in Table 1 . The types of LT included living-donor LT in 27 patients and deceased-donor LT in 6 patients. Six patients received ABO blood group-incompatible living-donor LT. The primary administered immunosuppressant included tacrolimus in all recipients, except 1 case of immunosuppression withdrawal, and 17 recipients (51.5%) also received adjunctive MMF. All of these patients demonstrated stable liver function at the time of blood sampling.
The correlation between the 12-hour trough concen- The healthy individuals were divided into 2 groups according to sex. Among the 76 male patients, the distribution of ImmuKnow ATP levels according to age is shown in Fig. 5A ImmuKnow assay results in patients with end-stage liver disease waiting for LT The ImmuKnow assay was performed on 85 adult patients with end-stage liver disease waiting for LT. All of these patients underwent LT within 2 weeks. The distribution of ImmuKnow ATP levels according to age is depicted in Fig. 6 , and there was a significant change with 
ImmuKnow results in healthy individuals
ImmuKnow assay results in LT recipients
The ImmuKnow assay was performed on 137 adult LT recipients, and their profiles are summarized at Table 1 .
The primary immunosuppressant administered to all recip- Interestingly, the results of our present study show that CNP activity is closely correlated with tacrolimus concentration, but this correlation became disrupted when MMF was concurrently administered. We speculate from this that MMF is involved in unknown mechanisms that affect calcineurin metabolism. In our present analysis, the inhibition of the enterohepatic cycle during cyclosporine co-administration explains some of the differences observed in the pharmacokinetics of MMF when co-administered with either tacrolimus or cyclosporine. 16 The co-administration of cyclosporine or tacrolimus differently affects the therapeutic drug monitoring of mycophenolic acid. The concurrent use of tacrolimus may decrease the mycophenolic acid concentration, thereby leading to an increased dose of MMF. 17, 18 Contradictory results have also been reported, in that co-administration with cyclosporine required significantly higher doses of MMF to achieve similar mycophenolic acid levels as tacrolimus-treated patients. 19 It has also been suggested that the cyclosporine-mediated inhibition of the biliary excretion of mycophenolic acid glucuronide by the multidrug resistance-associated protein-2 transporter is the mechanism responsible for the interactions between cyclosporine and MMF. 20 The ImmuKnow assay is specifically designed to assess the overall immune response in patients receiving immunosuppressive agents, and thus quantitatively estimate the risks of acute rejection and infection. As expected, we found very wide ranges of inter-and intraindividual varia- Further studies should be performed to identify other diagnostic methods that would enable predictive immune function monitoring.
